Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Halozyme Therapeutics, Inc.

HALO

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Last trade $95.85
Day change -$0.655 (-0.68%)
Day range $95.02 – $98.95
Volume 941,271
Market cap $11.00B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$11B
Price / earnings
22.66×
Price / book
-199.17×
Price / sales
6.1×
EV / sales
7.34×
EV / EBITDA
11.64×

Profitability

Earnings per share
$4.26
Return on assets
13.98%
Return on equity
-878.76%
Dividend yield
0%

Liquidity and leverage

Debt / equity
-58.84×
Current ratio
3.88×
Quick ratio
3.6×
Cash ratio
2.16×

Cash flow

Price / cash flow
12.25×
Price / free cash flow
12.42×
Free cash flow
$885.88M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for HALO, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$492.97M$481M$376.71M$451.77M$354.26M$325.72M$264.86M$298.01M
Cost of revenue$82.48M$79.17M$79.24M$78.77M$55.24M$46.36M$48.4M$42.06M
Gross profit$410.5M$401.83M$297.47M$373M$299.02M$279.36M$216.46M$255.95M
Selling, general and administrative$58.24M$57M$57.88M$77.03M$46.09M$41.61M$42.36M$42.25M
Research and development$27.78M$27.66M$25.56M$31.9M$17.25M$17.54M$14.8M$20.44M
Total operating expenses$115.53M$114.17M$112.95M$417.19M$81.1M$76.92M$74.92M$80.45M
Operating income$294.97M$287.65M$184.52M-$44.19M$217.92M$202.44M$141.54M$175.5M
Interest expense-$6.05M-$5.59M-$5.51M-$4.91M-$4.3M-$4.39M-$4.53M-$4.54M
Income before taxes$290.63M$284.9M$180.33M-$100.85M$218.96M$204.94M$143.83M$178.21M
Income taxes$43.58M$54.99M$30.28M$40.74M$43.73M$39.78M$25.73M$41.2M
Net income$247.05M$229.91M$150.05M-$141.59M$175.23M$165.16M$118.1M$137.01M
Net income attributable to common shareholders$247.05M$229.91M$150.05M-$141.59M$175.23M$165.16M$118.1M$137.01M
EBITDA$329.17M$321.62M$218.25M$267.38M$238.34M$222.94M$161.98M$195.92M
Basic earnings per share$2.17$1.96$1.27-$1.20$1.49$1.36$0.96$1.08
Diluted earnings per share$2.01$1.90$1.22-$1.16$1.43$1.33$0.93$1.06

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

HALO Rallies More Than 40% in 6 Months: How Should You Play the Stock?

Halozyme Therapeutics (HALO) has surged 43.1% over six months, outperforming the industry and S&P 500, driven by strong royalty revenues from its ENHANZE drug delivery technology partnerships. The company raised 2026 guidance with total revenues expected to reach $1.86-$1.925 billion and royalty revenues of $1.24-$1.26 billion. While recent acquisitions and proprietary product growth support long-term prospects, heavy reliance on partner companies for royalty income remains a key risk. Zacks rates the stock as a Hold.

Zacks Investment Research

Will HALO's Partner Royalties Drive Growth for the Rest of 2026?

Halozyme Therapeutics raised its 2026 revenue guidance to $1.86-$1.925 billion (33-38% YoY growth) and royalty revenue guidance to $1.24-$1.26 billion (42-45% YoY growth), driven by increased royalties from partnered drugs including J&J's Darzalex, argenx's Vyvgart Hytrulo, and Roche's Phesgo. The company's stock has rallied 53% year-to-date, though it trades at a premium valuation compared to the industry.

Zacks Investment Research

Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why

Halozyme Therapeutics (HALO) is highlighted as a strong growth stock pick with a Zacks Rank #1 and Growth Score of A. The company demonstrates exceptional earnings growth of 112.9% expected this year (versus 17.5% industry average), efficient asset utilization with an S/TA ratio of 0.64 (double the industry average of 0.34), and positive earnings estimate revisions. Sales are projected to grow 35.8% this year compared to 0% industry average.

Zacks Investment Research

TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up

TG Therapeutics reported Q3 2026 EPS of 35 cents and revenues of $259.9 million, both beating consensus estimates. Briumvi U.S. sales surged 52% to $232.6 million driven by physician adoption and patient growth. The company raised its 2026 global revenue guidance to $1 billion and expects Q4 U.S. Briumvi sales above $260 million. The stock rose 5.9% following the results.

Zacks Investment Research

NVIDIA Governance Woes: 3 Areas to Buy From Amid AI Market Slump

Following NVIDIA's governance controversy and 4.27% stock plunge, investors are advised to diversify away from concentrated AI exposure. The article recommends redirecting capital toward defensive sectors like healthcare and consumer staples, while maintaining selective semiconductor exposure through alternative players like TSMC and Semtech.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.